Computed tomography (CT) is increasingly available in veterinary practice. As for humans, CT has a tremendous potential in various clinical scenario. Oncology and traumatized dogs and cats are probably the veterinary patients that get more benefit from new CT applications. However, the most amazing progresses are in vascular and cardiac applications. The advent and rapid diffusion of advanced scanner technology (multidetector row) offer unparalleled diagnostic opportunity in daily practice for comprehensive evaluation of complex cardiovascular diseases. New skills and knowledge are necessary for radiologists and nonradiologists for understanding this revolutionary field of radiology.
- CT angiography
- cardiac CT
- vascular anomalies
- portosystemic shunt
- vascular ring anomalies
- cardiac diseases
Computed tomography (CT) is a cross‐sectional imaging modality based on the absorption of X‐rays in the patient. The overall performance of a CT system depends on several key components, comprising the X‐ray source, a high‐powered current generator, number of detectors, detector electronics, data transmission systems, and the computer system for image pre and post processing . CT angiography (CTA) first became possible with the advent of spiral CT in the early 1980s, which combined simultaneous continuous gantry rotation and table movement, succeeding the axial or step‐and‐shoot acquisition mode of conventional CT scanners [2, 3]. In this manner, the tube‐detector system takes a helical or spiral path around the patient moving through the gantry while the detectors collect the data. The
The scan volume is composed of thousands of volume elements (voxels). Ideally, for high‐quality images, voxels should be of equal dimensions in all three spatial axes (
2. Principles of MDCT angiography
The simultaneous acquisition of several sections not only results in an extremely increased scan speed but also in an extension of the CT scan range with isotropic resolution, which allow for reconstructing images in any arbitrary plane without loss of image quality. When properly used, MDCT scanners can provide high‐quality three‐dimensional (3D) mapping of the vasculature, allowing simultaneous evaluation of the vascular lumen, as well as the vessel wall and surrounding structures. Contrast medium (CM) is essential for CT angiography (CTA). In our patients, CM is usually injected through an intravenous catheter placed in a peripheral vein. When injected, CM reaches the heart and then travels throughout the body in the cardiovascular circulation. The goal of CTA is to achieve adequate opacification (magnitude of contrast enhancement) in the vascular territory of interest, within a certain time (timing of CM), and to maintain a consistent level of enhancement throughout scanning (shaping of CM) [6, 7]. CM concentration and injection protocol need to be adapted to the patient characteristics, the vascular territory of interest, and to take advantage of the capabilities of the MDCT scanner used. Intravascular attenuation of at least 300–400 HU along the full longitudinal extent of the target vasculature and throughout the duration of acquisition is considered to be a prerequisite for high‐quality CTA. Vascular contrast enhancement is influenced by various interacting factors: (1) patient‐related factors, (2) CM‐related factors, and (3) MDCT scanner‐related factors.
Principal patient factors that affect vascular enhancement are cardiac output and body weight. Veterinary patients have wide ranges of body weight and heartbeat. Thus, when designing a CTA protocol, it is essential to consider these characteristics to achieve high‐quality results consistently [8, 9]. In particular, the body weight is the most important patient‐related factor affecting the magnitude of contrast enhancement in vascular studies (they are inversely related). Interindividual variability in vascular contrast enhancement may be reduced by adjusting the overall iodine dose (by increasing CM volume and/or iodine concentration) and by increasing the injection rate proportional to body weight. The timing of CM is influenced by the cardiac output (inversely related). In patients with normal cardiac output, peak arterial contrast enhancement is achieved shortly after CM injection. In patients with decreased cardiac output, CM is distributed and clears slowly, leading to delayed and persistent peak arterial enhancement. In patients with higher cardiac output (small/toy breeds and cats or larger patients with diseases such as anemia or sepsis), CM distribution is unpredictable. A fixed scan delay is not recommended for CTA in veterinary patients.
Two methods are possible to predict how CM will behave in a given patient (injection individualization): (1) test bolus and (2) automated bolus triggering or bolus tracking. For the test bolus method, a small amount of CM is injected and multiple low‐dose nonincremental scans are taken over the region of interest (ROI) until the contrast is visualized in the selected vessel. For first generations of MDCT scanners (4–8 MDCT), this time can be used directly as the scanning delay for subsequent CTA. When using faster MDCT scanners, however, an additional time must be calculated to obtain a diagnostic delay, considering the scan speed, to not “outrun” the CM bolus. Using bolus‐triggering technique, test bolus injection is not necessary. All state‐of‐art MDCT systems feature this option. Multiple images are obtained over the ROI in a nonincremental manner during CM injection and the scan is initiated automatically when the density within the vessel exceeds a predetermined Hounsfield unit (HU) value.
A mechanical power injector is essential for MDCT angiography. This device allows preprogramming of the CM volume and flow rate and the setting of an injection pressure limit. Injection protocol parameters that may influence the opacification of target vessels are (1) injection duration (volume:rate), (2) rate of injection, and (3) volume of CM injected (duration × rate). In particular, arterial enhancement depends on the flow rate (mL/s). When the whole CM bolus is delivered at a constant injection rate (uniphasic injection), there is an upslope and downslope of the CM distribution curve and the vascular enhancement may be not uniform during volume acquisition [10, 11]. This characteristic is less important for short scan ranges (e.g., CTA of the liver, pancreas, etc.) or with newer fast scanners, but may be problematic when scanning larger vascular territories (e.g., aortoiliac CTA) or using slower CT scanners. Biphasic injection (a rapid phase, followed by a second slower phase) and multiphasic, exponentially decelerating techniques (multiphasic‐rate injection bolus with exponentially decreasing rate) provide more uniform enhancement with a longer plateau phase and may be indicated for larger volume coverage using slow scanners. In our experience, saline flushing following uniphasic CM bolus using same rate and of half‐to‐same volume (using a dual‐barrel injector system) effectively improves contrast distribution in the vascular system during acquisition.
3. MDCTA of vascular diseases
MDCT has brought about dramatic changes in veterinary vascular imaging during the past decade, leading to once unconceivable noninvasive diagnostic possibilities. Nowadays, CT‐angiography is reported to be the method of choice for
3.1. Thoracic CTA applications
The thoracic vascularization includes systemic vasculature and pulmonary vessels. Systemic arterial thoracic vasculature is provided by branches of the thoracic aorta. The pulmonary arteries supply 99% of the blood flow to the lungs and participate in gas exchange at the alveolar capillary membrane, while the bronchial branches of the bronchoesophageal artery supply the supporting structures of the lungs, including the pulmonary arteries. The pulmonary and bronchial arteries have rich and complex anastomoses at the capillary level. The venous drainage of the thorax is provided by cranial vena cava and azygos vein system. CM distribution after peripheral intravenous injection differs among the heart and the systemic and pulmonary arteries and veins, and this should be considered when designing a CT protocol. The delay between the start of CM injection and the initiation of scanning should be tailored based on scanner performance and the patient’s characteristics (using the bolus test or the bolus tracking technique, as said before). The ROI will be placed on different vascular structures, the aorta, or the main pulmonary artery, depending on the clinical purpose. Clinical indications for MDCTA of the thorax include anomalies of the aortic arch and its branches, bronchial and bronchoesophageal arterial anomalies, and systemic thoracic veins diseases [16–18]. Pulsatile artifacts are critical for the accurate diagnosis of aortic arch anomalies, especially in small veterinary patients. With slower 8–16‐MDCT scanners, acquisition of near‐isotropic dataset with spiral acquisition mode and a half‐scan interpolation reconstruction (50% overlap) algorithm aid the distinction between motion artifacts and intrinsic disease. Scanners with 40 or more rows can routinely imaging of the thoracic aorta using electrocardiogram (ECG) gating. At our center, which is equipped currently with a second‐generation DSCT scanner, all CT examinations of patients with suspected or known aortic arch pathologies or other cardiovascular anomalies are now ECG‐gated or acquired in sub‐second flash spiral mode, resulting in the freezing of cardiovascular and respiratory motions.
Most vascular ring anomalies found in dogs are
Enlarged bronchial branches of bronchoesophageal artery (
In oncology patients, MDCTA is indicated for the assessment and interventional planning in case of mediastinal masses or tumors of the thoracic wall involving the thoracic vasculature.
3.2. Abdominal vascular diseases
Most common abdominal vascular diseases involve the caudal vena cava and the portal system. Caudal vena cava anomalies often have no or little clinical significance in themselves, but they are often associated with other vascular anomalies, such as portosystemic shunts that are clinically relevant [20–22]. In veterinary literature, MDCT angiographic studies are frequently reported for congenital portosystemic shunt assessment in dogs and cats [23–26]. Moreover, it is widely used also for the assessment of other pathological conditions of the portal system, such as acquired portal collaterals (APSS), portal vein aneurysm, and portal vein thrombosis [27–29]. Congenital anomalies of the abdominal segment of the descending aorta are rarely reported in small animals, and include variable pattern of renal arteries, aortic aneurism, and common celiacomesenteric trunk. Among acquired conditions, local thrombosis in the distal aorta with embolization to the iliac and/or femoral artery is the most common indication for MDCTA in dogs and cats (Figure 5A).
The selection of an MDCTA scan protocol varies in consideration of the type of anomaly suspected and the vascular district (arterial, portal, or venous) potentially involved. For a comprehensive evaluation of the abdominal vascular structures, a multiphasic approach is necessary, including at least two vascular phases: arterial and portal venous phase that is also useful for the hepatic parenchyma evaluation. When CM is injected, opacification of the hepatic artery and its branches is encountered first, followed by the portal system, hepatic, and systemic veins. In veterinary literature, the peak aortic enhancement of normal dogs varies between 2 and 9.8 s, and peak enhancement of the portal vein varies between 14.6 and 46 s after contrast medium injection. Given the great diversity of patients’ characteristics (body weight and cardiac output), the use of bolus test or automatic bolus‐triggering techniques for the individualization of scan delays in multiphasic MDCT examinations is needed.
A dual‐ or three‐phase MDCT exam can provide excellent visualization of complex vascular anomalies and offer a comprehensive overview of the entire portal system and related parenchymal organs. Various new congenital and acquired phenotypes of portosystemic collaterals have been described using MDCT technology [24–26, 30] (Figures 6 and 7). Good opacification of the portal venous system allows detection of endoluminal filling defects in case of portal vein thrombosis and simultaneous assessment of secondary portal collaterals (portosystemic and/or portoportal collateral vessels) (Figure 8).
A third vascular phase, corresponding to the interstitial hepatic phase, allows optimal visualization of systemic veins, which is essential for the evaluation of venous thrombosis and vascular invasion (Figure 5B). Most caudal segments of the caudal vena cava are prone to congenital variation, which is generally clinically silent themselves (Figure 9), but are often associated with CPSS or other vascular and nonvascular anomalies that can be of great clinical relevance.
The arterial phase is useful for detection of high‐flow vascular connections (arteriovenous fistula) at any level of the body. MCDTA images show enlarged, tortuous arteries, and premature filling of the veins (Figure 10). In the liver, an early arterial phase can reveal complex hepatic arteriovenous malformations (HAVM) that are congenital anomalous connections between branches of the hepatic artery and hepatic portal vessels.
In traumatized patients, active bleeding due to arterial or venous vascular injuries can be revealed by CM extravasation in the arterial and portal venous phases. In oncology patients, a three‐phase MDCT abdominal examination provides useful information of vascular blood supply of tumors and local vascular invasion, allowing detailed interventional and surgical planning.
4. Cardiac CT
In humans, since the advent of advanced scanner technology having 64 or more detectors, the heart and coronary arteries are routinely imaged as a motion‐free volume of data. Most recent MDCT and DSCT scanners can obtain a true volumetric data set of the entire heart and adjacent structures that can be reconstructed at any point in the cardiac cycle, making CT an important imaging modality for the comprehensive assessment of cardiac morphology and function. While echocardiography remains the first‐line imaging modality, CT has become an increasingly utilized complementary imaging modality for assessment of coronary and noncoronary cardiac structures, including the cardiac chamber and valves, the pulmonary arteries and veins, the thoracic aorta and its proximal branches, the cardiac veins, and the pericardium.
Cardiac CT was first described in veterinary literature in 2011 for canine coronary artery assessment using a 64‐MDCT scanner . Later, other studies have been published describing morphological characteristics of various cardiac structures and comparing echocardiography, magnetic resonance (MR) and CT measurements [32, 33]. As for humans, cardiac CT in veterinary patients has now become an increasingly utilized modality for the assessment of cardiac congenital conditions, cardiac and paracardiac masses, and pericardial diseases [34–36]. In clinical practice, morphological evaluation of these conditions is generally performed with non‐ECG‐gated CT protocols, as a part of a thoracic CT examination. Most recent MDCT is not only fast but also has high spatial and temporal resolutions, multiplanar reconstruction (MPR) capabilities, and a wide field of view, which provides information of the heart, mediastinum, and adjacent structures, including the lungs. A non‐ECG‐gated CT examination, however, is not a reliable way for comprehensive evaluation of small cardiac structures (e.g., coronary arteries and valves), congenital heart diseases, cardiac sizes and in many other clinical situations using first generation of MDCT scanners (≤64 rows) [32, 33]. With most advanced MDCT scanners (e.g., 128–320 detector rows) and DSCT technology, it is possible to obtain high‐resolution, submillimetric data in a few seconds, providing excellent morphological detail of the heart and paracardiac structures, having minimal or no motion artifacts. For instance, at our center, now equipped with a second generation of dual‐source 128‐slice CT systems, cardiothoracic CT examination can be performed at a high‐pitch, up to 3.4 with gantry rotation time of 0.28 s and a temporal resolution of 75 ms (Figure 11).
4.1. Cardiac CT basic principles
For motion‐free and of diagnostic value imaging of the heart, high temporal and spatial resolution are both essential, especially in veterinary patients who have variable heart rates. CT data should be assessed during certain phases of the cardiac cycle with little cardiac motion. Ideally, a complete data set of the whole heart would be acquired within a single phase of the cardiac cycle without movement. Two methods are possible for virtually freezing the heart: prospective gating with sequential or step‐and‐shoot scanning mode and retrospective ECG gating (spiral) [37, 38].
The scanner technology available greatly influences the scan protocol for cardiac CT evaluation. The maximum pitch in single source MDCT is usually about 1.5. Last generation of DSCT scanners allow pitch value up to 3.4. This results in maximum scan speed of 737 mm/s, which allows continuous volume coverage of a whole body in one second or less with isotropic resolution . Since this impressive temporal resolution, pharmacological pretreatment for heart rate modulation is not necessary in our patients. High‐detailed images of the heart can be obtained also in awake patients, independently on the heart rate. However, using this approach, cardiac function evaluation is not possible. In our experience, low‐pitch retrospective ECG‐gated 128‐DSCT cardiac examination performed without any pharmacological pretreatment to reduce patient’s heart rate provides excellent images, useful either for morphological or functional assessments.
Factors influencing the CM hemodynamic distribution are similar to those described before for CTA. CM injection protocol should take into account the body weight and cardiac output of the patient. Both the bolus test and the bolus‐triggering techniques can be used for CM injection individualization for cardiac evaluation. In standard cardiac CT for coronary artery evaluation, the ROI is placed in the ascending aorta. In this approach, the left ventricular and left atrial walls and cavities, as well as left‐sided valves, will be uniformly opacified (Figures 12 and 13). However, depending on the contrast agent infusion protocol, the right‐sided chambers, walls, and valves may or may not be suitable for interpretation. Optimal timing for right heart good opacification can be achieved placing the ROI for test bolus or bolus tracking in the main pulmonary artery. Achievement of diagnostically adequate homogeneous enhancement of the right atrium can be difficult because of mixing of unopacified blood from the caudal vena cava with high‐attenuating contrast agent‐opacified blood from the cranial vena cava. Streak artifacts due to high concentration of CM in the cranial vena cava or right atrium may obscure some structures or simulate the presence of masses or thrombotic lesions. Dual or triple CM bolus injection technique may lead to a more uniform opacification of right‐sided cardiac structures. This may be necessary for the evaluation of patients with certain congenital heart diseases or cardiac masses.
4.2. Cardiac CT clinical applications
With ECG‐gated cardiac CT examination, the anatomy of the heart is clearly depicted. MDCT is the preferred imaging modality when anomalous origin and course of coronary arteries is suspected [32, 39] (Figure 14). Compared to human literature, reports of congenital artery anomalies in animals are sparse, presumably because coronary artery disease is less common in veterinary patients and rarely of clinical significance, unless in the setting of pulmonary valve stenosis (PS). Further, advanced diagnostic imaging of the heart is not routinely performed, thus underestimating the frequency of coronary anomalies in our patients. ECG‐gated cardiac CT allows the simultaneous evaluation of other noncoronary structures of the heart. Left and right chambers are well defined from the cardiac muscular wall and from interventricular and interatrial septum. Small structures, such as atrioventricular valves, aortic and pulmonary valves, papillary muscles of both ventricles, and trabeculae carneae are easily distinguishable .
Using retrospective ECG‐gated mode with full cardiac cycle available, functional evaluations of the heart are also possible. In postprocessing, multiplanar analysis (MPR) of volume dataset allows standard planar and volumetric measurements, using same image planes normally used in echocardiography [32–35]. ECG‐gated cardiac CT is also useful in patients with congenital cardiac defects such as PDA, PS, or more complex congenital heart diseases. Moreover, it is helpful for planning surgical and interventional procedures [16, 40] (Figures 15, 16).
In clinical practice, primary or metastatic cardiac tumors can be easily identified during routine non‐ECG‐gated examination of the thorax. However, ECG‐gated cardiac imaging in patients with suspected or known cardiac‐paracardiac or pericardial tumors minimizes motion‐related artifacts and allows a more precise delineation of the lesion margins (Figure 17).